10 [59] F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. [60] P. Laurent-Puig, A. Cayre, G. Manceau et al., “Analysis of PTEN, BRAF, and EGFR status in determining beneﬁt from cetuximab therapy in wild-type KRAS metastatic colon cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5924– 5930, 2009. [61] F. Loupakis, A. Ruzzo, C. Cremolini et al., “KRAS codon 61, 146 and BRAF mutations predict resistance to cetux- imab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer,” British Journal of Cancer, vol. 101, no. 4, pp. 715–721, 2009. [62] S. D. Richman, M. T. Seymour, P. Chambers et al., “KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude beneﬁt from oxaliplatin or irinotecan: results from the MRC FOCUS trial,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5931– 5937, 2009. [63] K. Cichowski and P. A. Ja¨nne, “Drug discovery: inhibitors that activate,” Nature, vol. 464, no. 7287, pp. 358–359, 2010. [64] P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen, “RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF,” Nature, vol. 464, no. 7287, pp. 427–430, 2010. [65] G. Hatzivassiliou, K. Song, I. Yen et al., “RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,” Nature, vol. 464, no. 7287, pp. 431–435, 2010. [66] S. J. Heidorn, C. Milagre, S. Whittaker et al., “Kinase- dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF,” Cell, vol. 140, no. 2, pp. 209– 221, 2010. [67] A. Duﬀy and S. Kummar, “Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors,” Targeted Oncology, vol. 4, no. 4, pp. 267–273, 2009. [68] S. Daouti, B. Higgins, K. Kolinsky et al., “Preclinical in vivo evaluation of eﬃcacy, pharmacokinetics, and pharmacody- namics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 134–144, 2010. [69] J. Y. Yoon, K. H. Koo, and K. Y. Choi, “MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy,” Cancer Research, vol. 71, no. 2, pp. 445–453, 2011. [70] C. Montagut and J. Settleman, “Targeting the RAF-MEK- ERK pathway in cancer therapy,” Cancer Letters, vol. 283, no. 2, pp. 125–134, 2009. [71] D. B. Solit, L. A. Garraway, C. A. Pratilas et al., “BRAF mutation predicts sensitivity to MEK inhibition,” Nature, vol. 439, no. 7074, pp. 358–362, 2006. [72] R. B. Corcoran, D. Dias-Santagata, K. Bergethon, A. J. Iafrate, J. Settleman, and J. A. Engelman, “BRAF gene ampliﬁcation can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation,” Science Signaling, vol. 3, no. 149, article ra84, 2010. [73] A. Di Cristofano and P. P. Pandolﬁ, “The multiple roles of PTEN in tumor suppression,” Cell, vol. 100, no. 4, pp. 387– 390, 2000. [74] H. K. Roy, B. F. Olusola, D. L. Clemens et al., “AKT proto- oncogene overexpression is an early event during sporadic colon carcinogenesis,” Carcinogenesis, vol. 23, no. 1, pp. 201– 205, 2002. Pathology Research International [75] M. Jhawer, S. Goel, A. J. Wilson et al., “PIK3CA muta- tion/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab,” Cancer Research, vol. 68, no. 6, pp. 1953–1961, 2008. [76] Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. [77] A. Sood, D. McClain, R. Seetharam et al., “Beyond KRAS: the quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. 3567. [78] D. W. Parsons, T. L. Wang, Y. Samuels et al., “Colorectal cancer: mutations in a signalling pathway,” Nature, vol. 436, no. 7052, p. 792, 2005. [79] C. A. Townsley, P. Major, L. L. Siu et al., “Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer,” British Journal of Cancer, vol. 94, no. 8, pp. 1136– 1143, 2006. [80] M. L. Rothenberg, B. LaFleur, D. E. Levy et al., “Randomized phase II trial of the clinical and biological eﬀects of two dose levels of geﬁtinib in patients with recurrent colorectal adenocarcinoma,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9265–9274, 2005. [81] J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger et al., “Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1892–1897, 2006. [82] T. Kuo, C. D. Cho, J. Halsey et al., “Phase II study of geﬁtinib, ﬂuorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5613–5619, 2005. [83] M. G. Zampino, E. Magni, C. Massacesi et al., “First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simpliﬁed FOLFOX6 as ﬁrst-line treatment for metastatic colorectal cancer,” Cancer, vol. 110, no. 4, pp. 752–758, 2007. [84] A. J. Weickhardt, T. J. Price, N. Pavlakis et al., “DUX study: a phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting Proceedings, abstract no. 3533. [85] J. R. Tonra, D. S. Deevi, E. Corcoran et al., “Synergistic antitumor eﬀects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy,” Clinical Cancer Research, vol. 12, no. 7, pp. 2197–2207, 2006. [86] N. C. Tebbutt, D. Kotasek, H. A. Burris et al., “Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC),” in Proceedings of the ASCO Annual Meeting, 2010, abstract no. 3538. [87] S. Kopetz, J. Desai, E. Chan et al., “PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. 3534. [88] C. Eng, J. Tabernero, E. Nowara et al., “Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): updated safety